All In Biotech

Drug Trial Radar · NCT07722741

Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

IMPACT31: A Randomized Open-label, Multi-center, Phase II Adjuvant Study of a Personalized Neoantigen DNA Vaccine (GNOS-PV02) and Plasmid Encoded IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Sep 2029

Study completion Jun 2032

Sponsor

Lead sponsor
Geneos TherapeuticsIndustry
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multi-site Phase II study of a personalized neoantigen DNA vaccine (GNOS-PV02) and plasmid encoded IL-12 (INO-9012) in subjects with histologically or cytologically confirmed diagnosis of HCC based on pathology report, who were eligible to undergo definitive resection, have demonstrated laboratory, radiographic and/or pathologic high-risk criteria for recurrence (described under eligibility), have no evidence of disease (NED) as per MRI approximately 28 days post resection, and are able to provide a tissue sample for personalized neoantigen DNA vaccine development.

Conditions

  • HCC

Interventions

  • GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporationBiological

    delivered by intradermal injection and electroporation

  • Electroporation DeviceDevice

    GNOS-PV02 + INO-9012 ID followed by electroporation

  • INO-9012Biological

    cytokine interleukin-12 (IL-12), a vaccine adjuvant

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence-free survivalTime frame: Up to 5 years

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Emory University

    Atlanta, Georgia · Not yet recruiting

  • Louisiana State University Health Sciences Center

    New Orleans, Louisiana · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Not yet recruiting

  • New York Presbyterian Hospital-Columbia University Irving Medical Center

    New York, New York · Not yet recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Not yet recruiting

  • Auckland City Hospital (Te Toka Tumai)

    Auckland, New Zealand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.